NCT02626507: Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

NCT02626507
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with IBC; Patients with a high tumor burden which includes more than one metastatic site in the liver or lung, and more than three metastatic sites in the bone; Active central nervous system (CNS), epidural tumor or metastasis, or brain metastasis
https://ClinicalTrials.gov/show/NCT02626507

Comments are closed.

Up ↑